Bemnifosbuvir/Ruzasvir (BEM/RZR) Achieved its Primary Endpoint of Statistical Non-inferiority Compared to Sofosbuvir/Velpatasvir (SOF/VEL; Epclusa®), a Standard-of-Care, in First-Ever [...] Read more »
New Analyses Advance Understanding of Long-Term Survival Outcomes with Mogamulizumab in Mycosis Fungoides and Sézary Syndrome
- Advanced analytical methods integrating clinical trial and real-world data address key evidence gaps in rare, difficult-to-treat blood cancers
- Read more »
New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome
- Clinically meaningful improvements in skin symptoms reported as early as week 4 and sustained over the 48-week study period
- Data presented at [...] Read more »
Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
PRINCETON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new data further defining the potential of mogamulizumab in the treatment of relapsed or [...] Read more »
Cronos Group Launches Premium Lord Jones® Brand in Israel, Advancing Borderless Product Strategy
TORONTO, Feb. 02, 2026 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON; TSX: CRON) (“Cronos” or the “Company”), a leading global cannabinoid company, today announced the launch of its Lord Jones® [...] Read more »
Kyowa Kirin Recupera Controle do Programa de Desenvolvimento e Comercialização do Rocatinlimab, Demonstrando Forte Compromisso para Abordar a Alta Necessidade Médica Não Atendida na Dermatite Atópica
- A Kyowa Kirin afirma o compromisso de desenvolver o rocatinlimab como um ativo diferenciado de mudança de vida com potencial de mercado significativo.
- Read more »
Kyowa Kirin reprend le contrôle du programme de développement et de commercialisation du rocatinlimab, manifestant ainsi son profond engagement visant à répondre aux besoins médicaux non satisfaits dans le domaine de la dermatite atopique
- Kyowa Kirin réaffirme sa volonté de développer le rocatinlimab comme un traitement innovant capable d’améliorer significativement la vie des patients, tout en [...] Read more »
Kyowa Kirin erlangt Kontrolle über Entwicklungs- und Kommerzialisierungsprogramm für Rocatinlimab wieder, zeigt starkes Engagement im Bereich des ungedeckten medizinischen Bedarfs bei atopischer Dermatitis
- Kyowa Kirin bestätigt Engagement für die Entwicklung von Rocatinlimab als lebensveränderndes differenziertes Feld mit bedeutendem Marktpotenzial.
- Read more »
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
- Kyowa Kirin affirms commitment to developing rocatinlimab as a life–changing differentiated asset with significant market potential.
- Rocatinlimab’s novel approach as an investigational [...] Read more »
Angelini Pharma Announces Appointment of Sergio Marullo di Condojanni as New CEO
ROME, Jan. 21, 2026 (GLOBE NEWSWIRE) — Angelini Pharma, part of the multinational privately owned industrial group Angelini Industries, today announced the appointment of Sergio Marullo di Condojanni as Chief [...] Read more »